Changes in U.S. policy have accelerated the implementation and use of electronic health records (EHRs) in the practice, disrupting physician workflow and decision making. In the meanwhile, reliance…
Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…
What Do Physicians and U.S. Payers Expect from the First-to-Market Therapies Targeting Geographic Atrophy? Geographic atrophy (GA) is the advanced dry form of age-related macular degeneration (AMD…
What Do Physicians and U.S. Payers Expect from the First-to-Market Therapies Targeting Geographic Atrophy? Geographic atrophy (GA) is the advanced dry form of age-related macular degeneration (AMD…
Last Updated 22 May 2014 Although colectomy is curative for the potentially fatal immune disease ulcerative colitis (UC), this procedure is life altering, and therefore unmet need remains for…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive) metastatic…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil…
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive) metastatic…
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
Chronic myeloid leukemia (CML) in China presents a huge challenge for healthcare providers but is a considerable opportunity for drug manufacturers. The launch of Novartis’s Glivec (imatinib), an…
The rising cost of healthcare is a global theme. As multinational pharmaceutical companies shift their focus from mature Western markets to the emerging Asian markets, it is vital to understand the…
Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/remitting…